BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31959113)

  • 21. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
    Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
    Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose treatment for paucibacillary leprosy; field implications.
    Revankar CR; Pai VV; Samy MS; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):312-4. PubMed ID: 10575415
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical-pathological conference: case 3.
    Hall JM; Torske KR; Kahn MA; Moreland AA; Moschella SL
    Head Neck Pathol; 2010 Sep; 4(3):226-9. PubMed ID: 20676829
    [No Abstract]   [Full Text] [Related]  

  • 24. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.
    Ji B; Sow S; Perani E; Lienhardt C; Diderot V; Grosset J
    Antimicrob Agents Chemother; 1998 May; 42(5):1115-20. PubMed ID: 9593137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose treatment for paucibacillary leprosy; clinical problems and management.
    Pai VV; Bulchand HO; Revankar CR; Ganapati R
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):310-2. PubMed ID: 10575414
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Hungria EM; Bührer-Sékula S; Oliveira RM; Aderaldo LC; Pontes MAA; Cruz R; de Gonçalves HS; Penna MLF; Penna GO; Stefani MMA
    Front Immunol; 2018; 9():915. PubMed ID: 29867930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised controlled trial assessing the effect of adding clarithromycin to rifampicin, ofloxacin and minocycline in the treatment of single lesion paucibacillary leprosy in Agra District, India.
    Girdhar A; Kumar A; Girdhar BK
    Lepr Rev; 2011 Mar; 82(1):46-54. PubMed ID: 21644471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study on trend of relapse in leprosy and factors influencing relapse.
    Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
    Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?
    Lockwood DN
    Lepr Rev; 1997 Dec; 68(4):299-300. PubMed ID: 9503865
    [No Abstract]   [Full Text] [Related]  

  • 30. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up.
    Ganapati R; Revankar CR; Pai VV; Kingsley S
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413
    [No Abstract]   [Full Text] [Related]  

  • 31. Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
    Maghanoy A; Mallari I; Balagon M; Saunderson P
    Lepr Rev; 2011 Mar; 82(1):65-9. PubMed ID: 21644473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single dose multidrug therapy for single lesion paucibacillry leprosy.
    Salafia A
    Indian J Lepr; 1998; 70(2):216-9; author reply 219-21. PubMed ID: 9724861
    [No Abstract]   [Full Text] [Related]  

  • 33. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
    Yang J; Kong J; Li B; Ji Z; Liu A; Chen J; Liu M; Fan Y; Peng L; Song J; Wu X; Gao L; Ma W; Dong Y; Luo S; Bao F
    J Infect; 2023 Apr; 86(4):338-351. PubMed ID: 36796681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
    Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ofloxacin containing combined drug regimens in the treatment of multibacillary leprosy.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    Southeast Asian J Trop Med Public Health; 1997 Dec; 28(4):803-10. PubMed ID: 9656405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Underlying mechanisms of leprosy recurrence in the Western Amazon: a retrospective cohort study.
    Gonçalves FG; Belone AFF; Rosa PS; Laporta GZ
    BMC Infect Dis; 2019 May; 19(1):460. PubMed ID: 31118048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of leprosy in the federated states of micronesia by intensive case finding, treatment with WHO/MDT and administration of chemoprophylaxis.
    Diletto C
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S10-3. PubMed ID: 10700929
    [No Abstract]   [Full Text] [Related]  

  • 38. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): reactions frequency in multibacillary patients.
    Penna ML; Buhrer-Sékula S; Pontes MA; Cruz R; Gonçalves Hde S; Penna GO
    Lepr Rev; 2012 Sep; 83(3):308-19. PubMed ID: 23356032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.